Network origin in Malin Hultqvist Hopkins first degree
| Entity | Entity type | Industry | |
|---|---|---|---|
Redoxis AB
 Redoxis AB Medical SpecialtiesHealth Technology Redoxis AB focuses on preclinical drug development and validation in autoimmune diseases. The firm focuses on preclinical development of small molecules that target molecular pathways in the immunological responses associated with autoimmune diseases such as rheumatoid arthritis and multiple sclerosis. The company was founded by David Rikard Martinsson Holmdahl and Jan Peter Olofsson in 2007 and is headquartered in Gothenburg, Sweden.
3
| Holding Company | Medical Specialties | 3 |
Chart of Companies connected to the second degree
Multi-company connection
Companies connected to Malin Hultqvist Hopkins via their personal network
| Company | Sector | Related people | Main position |
|---|---|---|---|
| Karolinska Institutet | College/University | Corporate Officer/Principal | |
Arexis AB
 Arexis AB Pharmaceuticals: MajorHealth Technology Arexis AB develops and manufactures pharmaceutical products. Its products are used for molecular dissection of metabolic and inflammatory diseases. The company was founded in 1999 and is headquartered in Goteborg, Sweden. | Pharmaceuticals: Major | Corporate Officer/Principal | |
| University of Stockholm | College/University | Corporate Officer/Principal | |
| University of Turku | College/University | Corporate Officer/Principal | |
| University of Lund | College/University | Corporate Officer/Principal Doctorate Degree | |
| University of Gothenburg | College/University | Masters Business Admin | |
Glucox Biotech AB
 Glucox Biotech AB Pharmaceuticals: MajorHealth Technology Glucox Biotech AB is a holding company. It develops clinically applicable therapeutics for treatment of type 2 diabetes; hyperglycaemia, insulin resistance and resulting complications. The firm explores new ideas for the prevention of cellular damage in ischemic stroke and heart infarction, as well the idea behind Glucox Biotech's therapies is to reduce oxidative stress by preventing the intracellular formation of reactive oxygen species. The company was founded by Ellen Mona Gratia Wilcke and Per Ingvar O. Wikström on July 1, 2003 and is headquartered in Stockholm, Sweden. | Pharmaceuticals: Major | Chief Executive Officer | |
ProNoxis AB
 ProNoxis AB Pharmaceuticals: MajorHealth Technology ProNoxis AB develops small-molecule drugs to treat chronic inflammation. The company was founded in 2009 and is headquartered in Lund, Sweden. | Pharmaceuticals: Major | Director/Board Member Chief Executive Officer |
Statistics
International
| Sweden | 9 |
| Finland | 2 |
| United States | 2 |
Sectoral
| Consumer Services | 6 |
| Health Technology | 4 |
| Commercial Services | 2 |
Operational
| Corporate Officer/Principal | 9 |
| Director/Board Member | 6 |
| Chief Executive Officer | 3 |
| Founder | 2 |
| Chairman | 1 |
Most connected contacts
- Stock Market
- Insiders
- Malin Hultqvist Hopkins
- Company connections
